- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Hodgkin lymphoma
- Meeting Date: July 2026
Brentuximab vedotin – July 2026
- Powder for I.V. infusion 50 mg
Public Summary Documents
Last updated
13 November 2026
